iSAEC, UC San Diego collaborate on DIRI genetics research
The partnership will follow a research strategy that focuses on key causal drugs and diverse populations groups that experience the adverse drug reaction. The iSAEC chairman Arthur Holden
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).